Janssen Pharmaceutica Nv

Boehringer Ingelheim Pharmaceuticals, Inc.

Michael Peter Winters

Zhihua Sui

Mark R Player

Charles Lawrence Cywin

Joachim Heider

James M Rinker

Bao-Ping Zhao

Scott E Jakes

Mark A Bobko

Renee L Des Jarlais

Jeremy Mark Travins

Kristi A Leonard

Maxwell David Cummings

Shelley K Ballentine

Nalin L Subasinghe

Heather Rae Hufnagel

Ehab Khalil

Farah Ali

Joan M Gushue

Allen B Reitz

Mark J Macielag

Yue-Mei Zhang

Mark James Wall

Sanath K Meegalla

James C Lanter

Christopher M Flores

Hidenori Takahashi

Dennis J Hlasta

Lei Qiao

Edward Charles Lawson

Roger John Snow

Hui Huang

Yifang Huang

Kimberly White

Ho Yin Lo

Peter Allen Nemoto

Brett A Tounge

Shyamali Ghosh

Michael H Parker

Brian Nicholas Cook

Eric D Strobel

Joerg Bentzien

Ji Wang

Carsten Schubert

Gregory Paul Roth

Nagy E Fawzy

Roman Wolfgang Fleck

Fu-An Kang

Steven S Pullen

Kevin J Moriarty

The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.

Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein U, U, U, R, R, Z, and W are defined herein.

Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes

The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Bicyclic pyrrole derivatives useful as agonists of GPR120

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R, R, R, Q, and G are defined herein.

Cyclopentylpyrazoles as N-type calcium channel blockers

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R, R, R, Q, and G are defined herein.

Pyrrolopyrazoles as N-type calcium channel blockers

The present invention comprises compounds of Formula (I). wherein: R, R, R, R, R, R, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Fused cyclopentyl antagonists of CCR2

The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Alkynyl derivatives useful as DPP-1 inhibitors

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare as defined in the specification, as are A Z, Q, Rand R.

Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed are compounds of formula (I): wherein R, R, Rand Rare defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

1,6 Naphthridines useful as inhibitors of SYK kinase

1,6 naphthyridines useful as inhibitors of SYK kinase

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare defined in the specification, as are A Z, Q, Rand R.

1,6 Naphthyridines useful as inhibitors of SYK kinase

Disclosed are substituted benzimidazole compounds of formula (I): wherein R, R, R, Rand Xare defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

Substituted benzimidazole compounds

Growing community of inventors

Morgantown, PA, United States of America

Michael Peter Winters